The Proof

The Proof

82 Clinical Trials.
5,026 People.

Black seed oil is one of the most tested natural compounds for blood sugar on earth. Here are the numbers that matter, with a link to every study.

−1.52A1C points in 12 weeks
−27points fasting glucose in type 2 diabetics
69%hit their A1C target, vs 21% on metformin alone
+56%kidney filtering power in 12 weeks

Fasting Blood Sugar

Every major review that pooled the trials found fasting blood sugar came down. In people with type 2 diabetes, the average drop was 18 to 27 points, on top of the medication they were already taking.

  • Muscle uptake. Seed extract drove insulin-like glucose uptake in C2C12 skeletal-muscle cells by phosphorylating AMPK and activating Akt, the same two switches exercise and insulin use to move GLUT4 to the cell surface (Benhaddou-Andaloussi 2010).
  • Insulin signalling. Hederagenin saponins from the seed restored the IRS → PI3K → Akt cascade and raised GLUT4 in insulin-resistant 3T3-L1 fat cells (Liu 2022). PPAR-γ activation, the target of the drug pioglitazone, showed up in 5 animal studies.
  • Liver output. Fasting glucose is mostly sugar your liver releases overnight. Animal studies show the gluconeogenic enzymes G6Pase and PEPCK suppressed, so less glucose leaves the liver.
  • Oxidative stress. Thymoquinone is a lipophilic quinone. It partitions into membrane lipids and breaks lipid-peroxidation chains from inside, with MDA down in 34 of 142 animal studies. It also upregulates glutathione, SOD and catalase through Nrf2, so the cell makes its own antioxidants again.
Review of 11 trials
−27points

Lower fasting blood sugar in type 2 diabetics

When the researchers looked only at people with type 2 diabetes, fasting glucose dropped almost 27 points on average.

Saadati et al., 2022 · Frontiers in Nutrition · 11 trials, 666 people
Read the study ↗
Study details: Meta-analysis of 11 randomized trials (prediabetes and type 2 diabetes, 666 people). Type 2 diabetes subgroup: fasting glucose −26.65 mg/dL (95% CI −38.24 to −15.06), p<0.001.
Review of 16 trials
−21points

Across 16 trials in type 2 diabetes

A 2025 review of 16 trials, all in people with type 2 diabetes, found fasting glucose fell 21 points on average.

Karimi et al., 2025 · Complementary Therapies in Medicine · 16 trials
Read the study ↗
Study details: Meta-analysis of 16 randomized trials, type 2 diabetes only. Fasting glucose −21.43 mg/dL (p=0.005). A1C −0.44% (p=0.01). LDL −19.53 mg/dL (p=0.003).
Placebo-controlled
−65points

In just 8 weeks, on black seed oil

Type 2 diabetics taking 1,000 mg of black seed oil a day went from a fasting glucose of 219 down to 154 in 8 weeks.

Kooshki et al., 2020 · Phytotherapy Research · 50 people, double-blind
Read the study ↗
Study details: Double-blind, placebo-controlled. 1,000 mg/day black seed oil (two capsules) for 8 weeks. Fasting glucose 219 → 153.6 mg/dL (p<0.001). Total cholesterol, triglycerides and LDL fell, HDL rose (all p<0.001).
Placebo-controlled
118 → 91

From prediabetic to normal in 8 weeks

Women with metabolic syndrome started in the prediabetic range and finished in the normal range. The placebo group barely moved (118 to 114).

Shirazi et al., 2020 · Endocrine · 140 women, double-blind, zero dropouts
Read the study ↗
Study details: Double-blind, 500 mg/day seed extract vs starch placebo, 8 weeks, diet and exercise in both groups. Fasting glucose −27.1 vs −4.2 mg/dL (p<0.001). Total cholesterol −22.2 vs −1.7 mg/dL.
12-week trial
−33points

Lower blood sugar after meals

Two hours after eating, blood sugar fell from 289 to 256 on 2 grams a day of black seed.

Bamosa et al., 2010 · Indian J Physiol Pharmacol · 94 people with type 2 diabetes
Read the study ↗
Study details: Randomized dose-ranging trial: 1, 2 or 3 g/day seed capsules added to existing oral diabetes medication for 12 weeks. 2 g/day group: 2-hour post-meal glucose 289 → 256 mg/dL.
82 trials
5,026

People in the biggest review ever done

The largest review so far pooled 82 randomized trials and found fasting glucose and A1C both dropped significantly.

Jafari et al., 2025 · Pharmacological Research · 82 trials, 5,026 people
Read the study ↗
Study details: Systematic review and meta-analysis of 82 randomized controlled trials, 5,026 participants. Fasting glucose and A1C both significantly reduced.

A1C

A1C is your 3-month blood sugar average, the number your doctor watches. In the trials it came down, and in one study it held for a full year while the placebo group got worse.

  • What A1C is. Non-enzymatic glycation of the N-terminal valine on hemoglobin's β-chain. It forms at a rate proportional to mean plasma glucose across the ~120-day red-cell lifespan.
  • Lever 1: lower mean glucose. Every mechanism in the Blood Sugar section lowers the average glucose that drives glycation.
  • Lever 2: direct anti-glycation. N. sativa essential oil inhibited hemoglobin glycation in vitro with an IC50 of 0.093 mg/mL (Bouyahya 2022). The same reaction produces AGEs (advanced glycation end-products), which cross-link collagen in kidney, retina and nerve.
12-week trial
−1.52

A1C points in 12 weeks

At 2 grams a day, A1C went from 9.09 to 7.57. At 1 gram a day, nothing significant happened. The dose matters.

Bamosa et al., 2010 · 94 people with type 2 diabetes
Read the study ↗
Study details: 2 g/day for 12 weeks: A1C 9.09 → 7.57%, fasting glucose 219 → 162 mg/dL. 3 g/day added no further benefit. 1 g/day was not significant.
90-day trial
69%vs 21%

Hit their A1C target

With thymoquinone (the active compound NOVINA is standardized to) added to metformin, 69% got their A1C under 7. On metformin alone, 21% did.

Ali et al., 2021 · Drug Research · 60 people with type 2 diabetes
Read the study ↗
Study details: Open-label, 90 days. Thymoquinone 50 mg/day + metformin: A1C 7.2 → 6.7%. Reached A1C under 7%: 69.2% vs 21.4% on metformin alone. Post-meal glucose −51.9 vs −29.5 mg/dL. No hypoglycemia.
1-year, placebo-controlled
12months

A1C stayed down all year

A1C dropped from 8.6 to 7.8 and stayed below where it started for 12 months. The placebo group's A1C rose from 8.2 to 8.5.

Kaatabi et al., 2015 · PLOS ONE · 114 people with type 2 diabetes
Read the study ↗
Study details: Placebo-controlled, participant-blinded, 2 g/day seed powder for 12 months. A1C 8.6 → 7.8% at 6 months, 8.2% at 12 months. Placebo 8.2 → 8.5%.
Review of 11 trials
−0.61

Average A1C drop in type 2 diabetics

Pooled across the trials in people with diagnosed type 2 diabetes, A1C came down 0.61 points on average.

Saadati et al., 2022 · Frontiers in Nutrition · 11 trials, 666 people
Read the study ↗
Study details: Type 2 diabetes subgroup of an 11-trial meta-analysis: A1C −0.61% (95% CI −0.83 to −0.39), p<0.001.

Your Pancreas

Your pancreas makes insulin. In type 2 diabetes it wears out. In the trials, the pancreas's insulin-making ability went up, not down.

  • Why beta cells fail. Chronic hyperglycemia and excess fatty acids (glucotoxicity and lipotoxicity) raise mitochondrial ROS inside beta cells, trigger caspase-3 apoptosis and shrink beta-cell mass.
  • Restoring secretion. Thymoquinone normalized glucose-stimulated insulin secretion (GSIS) in INS-1 beta cells and rodent islets under glucose overload, by regulating malonyl-CoA / acetyl-CoA carboxylase (ACC) through quinone redox cycling of NAD(P)H (Rezvani 2016).
  • Survival. In streptozotocin-damaged RIN-5F beta cells, thymoquinone nanoparticles raised viability from 43% to 70%. Across 142 animal studies, caspase-3/apoptosis markers fell in 13–15 and islet regeneration appeared on histology in 25.
  • In humans. This shows up as HOMA-β rising (45% → 64% in Bamosa 2010) while HOMA-IR falls.
12-week trial
45% → 64%

Insulin-making cells working again

Beta-cell function (how well your pancreas makes insulin) climbed from 45% to 64% in 12 weeks. Insulin resistance fell 26% in the same group.

Bamosa et al., 2010 · 94 people with type 2 diabetes
Read the study ↗
Study details: 2 g/day for 12 weeks. Beta-cell function (HOMA-β) 45% → 64%. Insulin resistance (HOMA-IR) 3.20 → 2.37.
1-year trial
46% → 59%

Still improving after a year

In the year-long trial, beta-cell function rose from 45.8% to 58.6%, and the body's own antioxidant defenses went up with it.

Kaatabi et al., 2015 · PLOS ONE · 114 people
Read the study ↗
Study details: 2 g/day for 12 months. Beta-cell function 45.8% → 58.6%. HOMA-IR 3.0 → 2.5. Total antioxidant capacity, catalase and glutathione rose; oxidative damage (TBARS) fell.
Lab study
2x

Nearly doubled insulin release

Pancreas cells exposed to black seed released almost twice the insulin (5.3 to 10.0), level with a prescription diabetes drug (10.3).

Islam et al., 2019 · Bioscience Reports · isolated pancreas cells
Read the study ↗
Study details: Isolated rat pancreatic islets at 11 mM glucose: insulin release 5.31 → 9.97 ng/mg with 200 µg/mL extract, vs 10.31 for the drug glibenclamide.
Placebo-controlled
−1.02

Insulin resistance, down almost 4 times more than placebo

In people with fatty liver, 2 grams a day cut insulin resistance (HOMA-IR) by 1.02, against 0.28 on placebo. Fasting insulin fell with it.

Darand et al., 2019 · Phytotherapy Research · 50 people
Read the study ↗
Study details: Lifestyle + 2 g/day seed vs lifestyle + placebo, 12 weeks, fatty liver. HOMA-IR −1.02 vs −0.28 (p=0.021). Insulin −3.87 vs −1.07 (p=0.027). QUICKI up (p=0.002). Liver fat down (p=0.005).

Your Kidneys

High blood sugar damages the kidneys over time. In patients whose kidneys were already struggling, black seed oil improved every kidney number the doctors measured.

  • The damage. Diabetic nephropathy runs on hyperglycemic ROS, AGE–RAGE signalling and NF-κB-driven inflammation. These thicken the glomerular basement membrane and strip podocytes, so protein leaks into the urine and GFR falls.
  • In human trials. Black seed oil lowered MDA (lipid peroxidation) and hs-CRP, and raised total antioxidant capacity and SOD (Rahmani 2022, diabetics on dialysis).
  • In animals. 26 of 142 animal studies measured the diabetic kidney. Across the animal studies, NF-κB fell in 7 and TNF-α in 15.
12-week trial
+56.5%

More kidney filtering power (GFR)

GFR, how well your kidneys clean your blood, rose from 23.4 to 36.6. The comparison group rose only 13%.

Ansari et al., 2016 · Asian J Pharm Clin Res · 143 kidney patients
Find the study ↗
Study details: Open-label, 2.5 mL/day oil + standard care vs care alone, 12 weeks, chronic kidney disease stage 3–4. GFR 23.42 → 36.64 mL/min vs 25.07 → 28.40 (p<0.001). 32% of the oil group had diabetic kidney disease.
12-week trial
−31.7%

Lower creatinine

Creatinine, the waste your kidneys are supposed to clear, fell from 2.93 to 2.00. Protein leaking into the urine dropped 45%.

Ansari et al., 2016 · 143 kidney patients
Find the study ↗
Study details: Creatinine 2.93 → 2.00 mg/dL vs 2.92 → 2.75. Urea −29.8% vs −10.6%. 24-hour urine protein 1.20 → 0.66 g vs 1.40 → 1.01 g. All p<0.001.
Placebo-controlled
8.26 → 7.76

A1C down, even in diabetics on dialysis

Diabetics on dialysis took 2 grams a day. A1C dropped half a point, inflammation fell and antioxidant defenses rose. Placebo: 8.38 to 8.32.

Rahmani et al., 2022 · Evid Based Complement Alternat Med · 46 people
Read the study ↗
Study details: Double-blind, 2 g/day oil for 12 weeks, diabetics on hemodialysis. A1C p=0.014 vs placebo. Fasting glucose 190.7 → 149.9 mg/dL (p=0.027). hs-CRP and MDA down, antioxidant capacity and SOD up.
3-month trial
0

Kidney or liver strain, compared with metformin

In a head-to-head trial, metformin raised liver (AST) and kidney (creatinine) markers. Black seed oil raised neither.

Moustafa et al., 2019 · Endocrine · people with type 2 diabetes
Read the study ↗
Study details: 3 months, 1.35 g/day oil vs metformin 2 g/day. Metformin raised AST and creatinine; the oil did not. The oil matched metformin on weight, waist, BMI and insulin sensitivity.

Your Liver

Fatty liver and high blood sugar feed each other. In placebo-controlled trials, black seed reduced liver fat and brought liver enzymes down.

  • The loop. Hepatic insulin resistance increases fat build-up in liver cells, and the fat drives more resistance. Injured hepatocytes leak ALT and AST into the blood.
  • What moved. Black seed lowered HOMA-IR, raised QUICKI (Darand 2019), and cut TNF-α, IL-6 and hs-CRP (Rashidmayvan 2019). NF-κB fell in the Darand companion paper, and ultrasound steatosis grade improved (Khonche 2019).
  • PPAR-γ. Activation of PPAR-γ, reported in 5 animal studies, improves insulin sensitivity and how the liver handles fatty acids.
Placebo-controlled
−32.6%

Lower liver enzyme (ALT)

In people with fatty liver, ALT fell 32.6% and AST fell 29.4% in 12 weeks, and the fatty-liver grade on ultrasound improved.

Khonche et al., 2019 · J Ethnopharmacology · 120 people
Read the study ↗
Study details: Placebo-controlled, standardized oil 2.5 mL twice daily (5 mL/day), 12 weeks, fatty liver. Steatosis grade down vs placebo (p=0.004). ALT −32.6%, AST −29.4%.
Placebo-controlled
−28points

Total cholesterol, fatty liver patients, 8 weeks

At just 1 gram a day, total cholesterol fell 28 points, triglycerides fell 29, HDL (the good one) rose 10.6, and liver enzymes came down.

Rashidmayvan et al., 2019 · J Diabetes Metab Disord · 44 people, 100% finished
Read the study ↗
Study details: Paraffin placebo-controlled, 1 g/day for 8 weeks, fatty liver. Total cholesterol −28.0 vs +0.8, triglycerides −29.5 vs −1.4, HDL +10.6 vs +0.6, LDL −23.4 vs −1.2 mg/dL. All p<0.01.

Cholesterol, Blood Pressure & Weight

The numbers that travel with blood sugar moved too. The review behind these rated its evidence "High", the top grade.

  • Lipids. Better hepatic insulin signalling means the liver exports less VLDL, so triglycerides fall and LDL follows. That's why lipids moved in the same trials as glucose.
  • Vessels. TNF-α and IL-6 activate the vessel lining. They fell in the NAFLD and PCOS trials, and the adhesion molecules ICAM-1 and VCAM-1 were among the outcomes the 82-trial review found improved (Jafari 2025).
  • Pooled effect. Weight −2.16 kg, BMI −0.51, blood pressure −3.25 / −2.75 mmHg, all at GRADE High certainty (Musazadeh 2026).
Review of 11 trials
−29points

Total cholesterol in type 2 diabetics

Total cholesterol dropped almost 29 points and LDL (the bad one) dropped 24 points on average.

Saadati et al., 2022 · 11 trials, 666 people
Read the study ↗
Study details: Type 2 diabetes subgroup: total cholesterol −28.74 mg/dL (95% CI −42.55 to −14.93). LDL −24.13 mg/dL (95% CI −33.81 to −14.45). Both p<0.001.
Review of 31 trials
−2.2kg

Weight down, blood pressure down

Across 31 trials: weight fell 2.16 kg (about 5 lbs) and blood pressure dropped 3.25 / 2.75. Evidence graded High.

Musazadeh et al., 2026 · Endocrinol Diabetes Metab · 31 trials
Read the study ↗
Study details: Meta-analysis of 31 randomized trials. Weight −2.16 kg, BMI −0.51, blood pressure −3.25 / −2.75 mmHg, fasting glucose −18.62 mg/dL. All rated GRADE High.

Head-to-Head With Metformin

Researchers put black seed oil up against the most prescribed diabetes drug in the world.

  • How metformin works. Metformin inhibits mitochondrial complex I and activates hepatic AMPK, mainly suppressing hepatic gluconeogenesis.
  • What black seed adds. It overlaps on AMPK, then adds targets metformin doesn't touch: beta-cell insulin secretion (islets 5.31 → 9.97 ng/mg, level with glibenclamide), intestinal SGLT1 blockade and α-glucosidase inhibition.
  • Why they stack. Complementary targets are additive. In mice, thymoquinone + metformin cut glucose 41.3% vs 32.5% for metformin alone (p=0.02). In people, 69% vs 21% reached A1C under 7% (Ali 2021).
6-month trial
=

Matched metformin in prediabetes

In obese prediabetics, 900 mg of black seed oil a day for 6 months performed statistically the same as metformin on blood sugar and body measurements.

Mostafa et al., 2021 · J Diabetes and Its Complications · 117 people
Read the study ↗
Study details: Three-arm randomized trial: 900 mg/day oil vs metformin vs lifestyle change, 6 months, obese prediabetics (NCT03925714). Oil statistically similar to metformin on blood sugar and body measurements. Only the oil improved the lipid panel and TNF-α.
90-day trial
3x

More people reached target when thymoquinone was added

Adding thymoquinone to metformin tripled the share of patients who got their A1C under 7: 69% vs 21%.

Ali et al., 2021 · Drug Research · 60 people
Read the study ↗
Study details: Reached A1C under 7%: 69.2% on thymoquinone 50 mg + metformin, 61.1% on thymoquinone 100 mg + metformin, 21.4% on metformin alone. 90 days, no hypoglycemia.

Safety

A full year of daily use, with doctors checking kidneys, liver and blood the whole time.

  • Organ monitoring. Kaatabi 2015 tracked liver (ALT, AST) and kidney (creatinine, urea) markers plus full blood counts for 12 months, with no abnormal change.
  • Against metformin. In Moustafa 2019, metformin raised AST and creatinine; black seed oil raised neither.
  • Adverse events. All mild and GI: 3 of 94 in Bamosa 2010 (gone when taken after meals), 4 of 35 transient nausea in Hosseini 2013, 8 of 72 mild GI or rash in Ansari 2016. No hypoglycemia in any trial.
1-year trial
12months

No recorded side effects

114 people took it every day for a year. The researchers recorded no side effects, and kidney, liver and blood counts stayed normal throughout.

Kaatabi et al., 2015 · PLOS ONE · 114 people
Read the study ↗
Study details: 114 randomized, 2 g/day for 12 months. The authors report no record of any side effect. Kidney function, liver function and blood counts stayed normal throughout.
Across the trials
0

Cases of dangerously low blood sugar

None of the human trials reported hypoglycemia, including patients already taking sulfonylurea drugs.

Bamosa et al., 2010 and Ali et al., 2021 among others
Read the study ↗
Study details: Bamosa 2010 added black seed to glibenclamide, metformin or rosiglitazone; Ali 2021 added thymoquinone to metformin. Neither reported hypoglycemia. 3 Bamosa patients had mild stomach upset that stopped when taken after meals.

How It Works

Lab studies show black seed working on blood sugar from several directions at once: more insulin from the pancreas, less sugar absorbed from food, and less sugar damage inside the body.

  • Digestion. The seed's phenolic fraction inhibited α-glucosidase 72.26% vs acarbose 70.90% (Kadri 2021), and its aqueous fraction inhibited pancreatic α-amylase with an IC50 of 0.031 mg/mL (Dalli 2021). Less starch becomes sugar.
  • Absorption. Aqueous extract blocked more than 80% of the sodium-glucose cotransporter SGLT1 current in rat jejunum (Meddah 2009). Less sugar crosses the gut wall.
  • Secretion. Insulin release from isolated islets nearly doubled, level with glibenclamide (Islam 2019). GSIS normalized under glucose overload via malonyl-CoA/ACC (Rezvani 2016).
  • Sensitivity and protection. AMPK, PI3K/Akt, GLUT4 and PPAR-γ for uptake. Nrf2-driven glutathione, SOD and catalase, plus anti-glycation, for protection. Most diabetes drugs work on one of these.
Lab study
80%+

Blocks sugar absorption in the gut

Black seed blocked more than 80% of the gut's sugar-absorbing channel (SGLT1) and improved glucose tolerance.

Meddah et al., 2009 · J Ethnopharmacology
Read the study ↗
Study details: Rat intestine: water extract inhibited the sodium-glucose transporter (SGLT1) current by more than 80%, and improved oral glucose tolerance in rats.
Lab study
72% vs 71%

Outperformed a prescription starch blocker

Black seed extract blocked the enzyme that turns starch into sugar (72.3%), slightly beating the prescription drug acarbose (70.9%).

Kadri et al., 2021 · Foods
Read the study ↗
Study details: Phenolic fraction of the seed inhibited α-glucosidase 72.26%, against 70.90% for acarbose at the same test conditions.
↑ Back to the top

Why NOVINA Goes Further

Most of these trials used ordinary black seed oil or ground seed, which carries about 0.2% to 0.5% thymoquinone, the active compound. They still moved A1C. NOVINA is standardized to 2%, verified every batch.

0.2–0.5%Ordinary black seed oil
2%NOVINA, 4 to 10x more
Start My 90 Days

Backed by the 90-Day Money-Back Guarantee.